Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

ABSTRACT: Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision medicine. First- and second-generation epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) are recommended as upfront therapy for EGFR-mutated advanced nsclc and, compared with chemotherapy, have resulted in superior progression-free survival, improved tumour response rates, and improved quality of life. However, resistance inevitably develops, and the third-generation tki osimertinib has been approved to target the gatekeeper EGFR mutation T790M, which is responsible for resistance in 60% of cases. Multiple drivers of tki resistance have now been identified, and many new drugs are in deve

SUBMITTER: O'Kane GM 

PROVIDER: S-EPMC6001758 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature